- Home
- XRN vs LXEO Comparison
XRN vs LXEO Comparison
Compare XRN & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XRN | LXEO |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | 30 | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.6M | 486.1M |
| IPO Year | 2016 | 2023 |
Fundamental Metrics
Financial Performance| Metric | XRN | LXEO |
|---|---|---|
| Price | $32.64 | $5.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $18.60 |
| AVG Volume (30 Days) | 158.1K | ★ 683.5K |
| Earning Date | 05-05-2026 | 03-13-2026 |
| Dividend Yield | ★ 8.74% | N/A |
| EPS Growth | N/A | ★ 75.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | $3.50 | N/A |
| Revenue Next Year | $3.13 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.29 | $1.45 |
| 52 Week High | $37.46 | $10.99 |
Technical Indicators
Market Signals| Indicator | XRN | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 29.70 | 30.29 |
| Support Level | N/A | $4.67 |
| Resistance Level | $37.18 | $7.77 |
| Average True Range (ATR) | 1.19 | 0.51 |
| MACD | -0.24 | -0.11 |
| Stochastic Oscillator | 0.00 | 4.90 |
Price Performance
Historical ComparisonAbout XRN Chiron Real Estate Inc. Common Stock
Chiron Real Estate Inc is a real estate investment trust focused on investing and actively managing critical healthcare infrastructure. Its portfolio includes Spectrum-Dumfries, Slippery Rock MOB, Gainesville Eye Center, Aurora Sports Health, and many Others. Geographically, the company has it's concentration in a small number of states, including Texas, Florida, Ohio, Arizona, Pennsylvania, and Illinois.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.